Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01, R21 Clinical Trials Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-20-168, which uses the R21 grant mechanism.

Deadlines:

  • R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  • R21 Due Dates: Feb. 16, Jun. 16, Oct. 16

PAR-20-165 Expiration Date March 06, 2023

Agency Website

Amount Description

 

Funding Type

Grant

Eligibility

Faculty

Category

Environmental & Life Sciences
Interdisciplinary
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 5, 2023